- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Wayne Winegarden, PhD Discusses the Potential Savings of Biosimilars
Wayne Winegarden, PhD discusses the potential savings inherent in biosimilars at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
Wayne Winegarden, PhD, is a senior fellow in business and economics as well as the Ddrector for the Standard for Medical Economics and Innovation at the Pacific Research Institute.
Transcript:
What does your research say about biologics and potential savings?
A lot of my recent research has been looking at biosimilars and specifically trying to quantify the amount of savings that are available, because we haven't had the market develop here the way you have seen biosimilars develop in Europe, nor the same way that you've seen generics developed to become 90% of market here, and one possibility is that the savings that we think areavailable aren't actually available. So, we went about looking at the actual price data, the actual volume data. We wanted to see what are the savings based on the current kind of pricing and volumes. And in fact, if you could get a substantial market share for biosimilars, there's a tremendous amount of savings, just in the 9 drug classes where there's either an actual competitor or a competitor that is authorized to compete against originator. We're talking somewhere between $2.4 and $7 billion in potential savings compared with a world without biosimilars. And that's an annual basis. To put that in perspective, between 2017 and 2018, the total spending on biologic drugs increased by $10 billion. So, if we could get to a 75% market share for biosimilars, which is less than the share for generic medicines, we could actually cut [spending on biologics] by 70%.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
